Eight Ashwagandha supplements scored on potency, purity, value, and transparency. Sourcing combines branded-extract clinical trials (KSM-66, Sensoril) with publicly available manufacturer COAs. How we evaluate.
Nutricost
The cleanest potency-per-dollar pick. KSM-66 (the most-studied branded extract) at the 600 mg daily dose used in most cognitive and cortisol RCTs, in a no-frills capsule with third-party Certificate of Analysis access on request.
Pros
Cons
Doctor's Best
A reputable specialist brand using the same KSM-66 extract as our Editor's pick, but dosed lower per capsule. Good entry point for first-time Ashwagandha users testing tolerance, but you may need 4 to 5 capsules per day to hit the trial-validated 600 mg dose, which erodes the value calculation.
Pros
Cons
Pure Encapsulations
The hypoallergenic option. Sensoril extract (root + leaf, 10 percent withanolides) at a 500 mg daily dose, in Pure Encapsulations' standard hypoallergenic capsule with no fillers, no binders, and no allergens. Premium price per active milligram, but readers with sensitivity to common excipients pay it for a reason.
Pros
Cons
NOW Foods
A solid mainstream-budget pick from a legacy GMP-certified brand. Not KSM-66 or Sensoril, but a generic root extract dosed at 450 mg per capsule, which lands in the same gross dose band as KSM-66 trials. Transparency stops at standardization (no branded-extract identification, no specific withanolide percent), so you are paying less and accepting less data.
Gaia Herbs
The traceability play. Gaia Herbs publishes a per-batch ID lookup (meetyourherbs.com) that ties each bottle to a farm, harvest, and lab-test set. Lower withanolide content than the branded extracts, but readers who care about supply-chain transparency over peak potency get more here than from any other brand in the panel.
Organic India
The whole-root traditionalist pick. Not an extract at all, just powdered USDA-organic ashwagandha root, which mirrors traditional Ayurvedic preparation but delivers far less withanolide content per capsule than a standardized extract. Readers buying Organic India are explicitly choosing supply-chain provenance over peak potency.
Himalaya
The botanical-identity play. Himalaya was an early adopter of TRU-ID DNA authentication for plant-source verification, which is meaningful for ruling out species adulteration but does not speak to active-fraction concentration. Whole-root preparation, no withanolide standardization, no per-batch COA exposed publicly. Listed for category completeness rather than as a clinical-evidence-first recommendation.
Solgar
The drugstore default. Solgar is a familiar national brand with broad retail distribution, and the 400 mg root extract is in the same gross dose band as competitors, but the absence of branded-extract identification, withanolide percentage, or per-batch COA pulls this down to the bottom of the panel on transparency. A reasonable pick if you only buy from large national brands and accept that level of opacity.
We aggregated publicly available manufacturer Certificates of Analysis (COAs) and PubMed-indexed trial data for each branded extract. Where a brand publishes lot-level COAs, we cite their reported withanolide content; where only label claims exist, we flag the transparency gap in the criteria scores. We do not commission our own lab tests, see our methodology article for the full detail.
Withanolide % vs. dose.
Heavy metals + microbial.
Cost per active mg.
Standardization + COA access.
Criterion
Standardized withanolide percent disclosed on the label and corroborated by a manufacturer Certificate of Analysis, weighed against the daily dose.
Criterion
Heavy-metals (lead, arsenic, cadmium, mercury) and microbial test results, where the brand publishes a per-batch COA, evaluated against USP-grade thresholds.
Criterion
Cost per milligram of total withanolides at the labeled daily dose, normalized across formats.
Criterion
Sourcing disclosure (root vs root + leaf), branded-extract identification (KSM-66, Sensoril, or generic), and public certificate-of-analysis access.
KSM-66 is root-only, standardized to about 5 percent withanolides, dosed 300 to 600 mg per day, and is more energizing in subjective reports. Sensoril is root + leaf, standardized to about 10 percent withanolides, dosed 125 to 250 mg per day, and tends to be more sedating. Both have replicated trial evidence on stress and cortisol. Pick KSM-66 if you want daytime alertness benefit, Sensoril if you want evening calm or sleep support. Do not mix them in the same daily regimen, the dose-response data lives at the branded-extract level.
The most replicated cognitive and stress trials use KSM-66 at 600 mg per day for 8 to 12 weeks (Chandrasekhar 2012, Choudhary 2017). Sensoril trials cluster at 125 to 250 mg per day. Below 300 mg of KSM-66 you are sub-clinical for cortisol effects; above 600 mg the marginal gain is not well-characterized. Whole-root powder is not directly comparable to standardized extracts because the active fraction is not standardized.
8 weeks on, 2 to 4 weeks off is a reasonable default. The trial evidence is strongest in the 8 to 12 week window, and adaptogen-class compounds do appear to lose marginal benefit when run continuously without breaks. Long-term safety beyond 6 months is less studied, and cycling preserves the option to detect non-supplement contributions to your stress baseline.
There is evidence that ashwagandha can mildly increase T3 and T4 in subclinical hypothyroid patients (Sharma 2018), which is benefit for that group but a flag for anyone with hyperthyroidism, Graves' disease, or active thyroid medication. If you are on levothyroxine, methimazole, or have a thyroid condition, talk to a clinician before starting and re-test labs at 8 to 12 weeks. This is the most clinically meaningful interaction in the ashwagandha literature.
The trial evidence does not support sex-specific dosing. KSM-66 trials at 600 mg per day enroll mixed-sex cohorts and report comparable cortisol and subjective-stress effects. Where sex-specific evidence does exist, it concerns secondary outcomes: testosterone in male athletic populations (Wankhede 2015) and sexual function in female cohorts (Dongre 2015). Default to the standard 600 mg KSM-66 or 250 mg Sensoril regardless of sex.
Pregnancy and lactation (insufficient safety data), active autoimmune flare-ups (immune-modulating effects are not well-characterized in that context), upcoming surgery within 2 weeks (potential CNS-depressant interaction with anesthesia), pre-existing hyperthyroidism or thyroid medication titration, and concurrent benzodiazepine or sedative-hypnotic use (additive sedation risk, especially with Sensoril). When in doubt, ask your clinician.
Probably yes for mild interactions, but discuss with your prescriber first. Ashwagandha has GABA-ergic activity and some MAO-A inhibition in vitro, which raises a theoretical interaction risk with SSRIs, MAOIs, and benzodiazepines. The clinical trial evidence in psychiatric-medicated cohorts is thin. Do not self-stack adaptogens on top of an SSRI without your prescriber's go-ahead.
Three things: proprietary 'stress relief' blends that hide the ashwagandha dose behind unrelated ingredients; labels that promise 'high potency' without disclosing whether the extract is KSM-66, Sensoril, or generic; and brands with active FDA warning letters for GMP violations. Not having a public batch-level COA is a flag but not a disqualifier; many credible brands gate COAs to support requests.
Because withanolide concentration is the variable that the trial evidence is built on, and standardized extracts deliver 5 to 10 percent withanolides while whole-root powder typically delivers under 1 percent. To match a 600 mg KSM-66 trial dose, you would need roughly 5 to 10 times the gross weight of whole-root powder, which erases the cost advantage. Whole-root has its place for traditionalist preparation, just do not expect it to be a substitute for the clinical trial dose.
